Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Assets Average (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Assets Average data on record, last reported at $548.4 million in Q4 2025.

  • For Q4 2025, Assets Average rose 45.59% year-over-year to $548.4 million; the TTM value through Dec 2025 reached $548.4 million, up 45.59%, while the annual FY2025 figure was $469.6 million, 46.18% up from the prior year.
  • Assets Average reached $548.4 million in Q4 2025 per TARS's latest filing, up from $514.8 million in the prior quarter.
  • Across five years, Assets Average topped out at $548.4 million in Q4 2025 and bottomed at $180.2 million in Q1 2022.
  • Average Assets Average over 5 years is $319.9 million, with a median of $287.1 million recorded in 2023.
  • Peak YoY movement for Assets Average: decreased 7.87% in 2023, then surged 81.47% in 2024.
  • A 5-year view of Assets Average shows it stood at $184.7 million in 2021, then increased by 17.6% to $217.2 million in 2022, then grew by 22.91% to $266.9 million in 2023, then surged by 41.11% to $376.6 million in 2024, then surged by 45.59% to $548.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets Average were $548.4 million in Q4 2025, $514.8 million in Q3 2025, and $497.9 million in Q2 2025.